Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00748657 · FLOW

Participant flow

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    FG000
    title
    Bevacizumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
The study was activated on 9/22/2008 and closed to accrual on 1/31/2011 (suspended from 1/4/2010 to 8/9/2010).
Complete source fields
groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    FG000
    title
    Bevacizumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
The study was activated on 9/22/2008 and closed to accrual on 1/31/2011 (suspended from 1/4/2010 to 8/9/2010).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice